Lung and Thoracic Cancer

Lung Nodule Screening Program Takes Advantage of Early Detection’s Link to Improved Lung Cancer Prognosis

Only about six percent of high-risk patients were screened for lung cancer in 2022, according to the American Lung Association. Advances in early detection for lung cancer, as well as new treatment options, have transformed this diagnosis, giving hope to many patients and families. With annual screening and early detection of lesions, lung cancer patients have a higher rate of survival.

Tarlatamab Provides Improved Outcomes for Previously Treated Small Cell Lung Cancer

Now FDA-approved, tarlatamab—the first bispecific T-cell engager (BiTE) therapy for solid tumors—offers new hope for patients with previously treated small cell lung cancer. Learn how this novel agent targets tumor cells and how the University of Maryland Medical System team of experts manage immune-related side effects while working closely with referring physicians to deliver advanced care.